A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer
This is a pilot study to gather preliminary data on the baseline immunologic status of
patients with HER-2(+) breast cancer and to establish an immune monitoring laboratory for
future clinical trial. We will ask up to 10 patients with HER-2(+) breast cancer in stable
condition and in reasonable health to participate in this study. The study will establish
an immune monitoring for correlative studies done in patients with HER-2(+) breast cancer.
The immunologic tests that will be done are ELISpot, lymphocyte proliferation, intracellular
cytokine staining, lymphocyte immunophenotyping, and ELISA.
Observational
Time Perspective: Retrospective
Dr. Ellie Guardino MD/PhD
Principal Investigator
Stanford University
United States: Institutional Review Board
BRSADJ0009
NCT00477139
January 2009
September 2010
Name | Location |
---|---|
Stanford University School of Medicine | Stanford, California 94305-5317 |